Pharsight

Izba is owned by Novartis.

Izba contains Travoprost.

Izba has a total of 4 drug patents out of which 0 drug patents have expired.

Izba was authorised for market use on 15 May, 2014.

Izba is available in solution/drops;ophthalmic dosage forms.

The generics of Izba are possible to be released after 10 October, 2029.

Application	Filing Date	Opposition Party	Legal Status
EP15202422A	2018-02-12	actrevo GmbH	Granted and Under Opposition
EP15202422A	2018-02-09	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15202422A	2018-02-09	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP15202422A	2018-02-07	Bausch & Lomb Incorporated	Granted and Under Opposition
EP15202422A	2018-02-01	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP12193597A	2018-01-26	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP12193597A	2018-01-26	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-29	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-16	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09722278A	2016-02-12	Pohlman, Sandra M.	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (5 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (6 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (6 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (6 years from now)